Background: Inflammation drives clinical progression in HIV-infected persons. Antiretrovirals (ARV) partially reduce inflammation. We studied the effect of persistent inflammation on clinical failure during ARV among multi-country ACTG 5175 trial participants.
Methods: In a nested case-control study, cases were clinical failure, defined as incident WHO stage 3/4 HIV disease or death from weeks 24 to 96 weeks; controls were without clinical failure and randomly selected. IL-6, IP-10, IL-18, TNFα, IFNγ and sCD14 levels were measured pre-ARV and at week 24 of ARV (ARV24). Persistent inflammation was defined as highest quartile levels (>Q3) pre-ARV and at ARV24 for IL-6(>48.3pg/mL),IP-10(>2856pg/mL),IL-18 (>774pg/mL), sCD14 (>6.4log10pg/mL), TNFα(>28.4pg/mL), and IFNγ(>48pg/mL), compared to lower quartiles(≤Q3). Poisson regression analysis was used to estimate RRs, adjusting for baseline age, sex, treatment, country, CD4, log10HIV RNA, prevalent TB, and viral suppression at ARV24 (HIV RNA<400 cp/ml).
Results: Of 99 cases and 233 controls, available samples were tested (Figure). Median age was 34 years; 160 (48%) were females. Median (IQR) CD4 was 181 (96-229) cells/μL and median (IQR) HIV RNA level was 5 (4.5-5.5) log10 cp/mL. At ARV24, 276 (87%) persons were virologically suppressed; median (IQR) CD4+ T cell count was 290 (197-388) cells/μL. Persistently high levels of IL-18 and sCD14 at ARV24 were independently associated with clinical failure [IL-18 RR (95%CI) 3.59 (1.48–8.74), p<0.05; sCD14 RR (95%CI) 2.21 (1.01–4.80), p<0.05]. High levels of IFNγ were independently associated with decreased risk of clinical failure [RR (95%CI) 0.08 (0.01–0.66), p<0.05]. Other markers at ARV24 were not associated with clinical failure. Restricting the analysis to subjects who were virologically suppressed at ARV24 maintained associations with IL-18 and IFNγ [IL-18 RR (95%CI) 3.10 (1.08–9.02), p<0.05; IFNγ RR (95%CI) 0.07 (0.01 – 0.64), p<0.05]; the association with sCD14 diminished in significance [RR (95%CI) 2.0 (0.77 – 5.25), p=0.16].
Conclusions: IL-18, a highly pro-inflammatory cytokine linked to organ damage, was associated with clinical failure in persons who were virologically suppressed in diverse settings, suggesting that persistent inflammation in HIV-infected persons on ARV may contribute to further disease progression. Unexpectedly, IFNγ levels were inversely related to the risk of clinical failure, suggesting a link with immune restoration.
Figure. Kaplan-Meier survival estimates of HIV-infected persons initiating ARV in multi-national settings and their rate of developing clinical failures in persons with high (>Q3) compared to low (≤Q3) inflammatory marker levels.